|1.||Marques, M Matilde: 2 articles (11/2007 - 10/2002)|
|2.||Gamboa da Costa, Gonçalo: 2 articles (11/2007 - 10/2002)|
|3.||Beland, Frederick A: 2 articles (11/2007 - 10/2002)|
|4.||Wang, Yu-Ping: 1 article (11/2007)|
|5.||Churchwell, Mona I: 1 article (11/2007)|
|6.||Doerge, Daniel R: 1 article (11/2007)|
|7.||Fu, Xin: 1 article (11/2007)|
|8.||Kupfer, David: 1 article (10/2005)|
|9.||Parte, Priyanka: 1 article (10/2005)|
|10.||Duffel, Michael W: 1 article (12/2004)|
10/01/2002 - "In a recent study [Gamboa da Costa et al., Cancer Lett., 176, 37-45 (2002)], we demonstrated a significant increase in the mutant frequency in the lacI gene of Big Blue rats treated with tamoxifen, and a further increase in rats administered alpha-hydroxytamoxifen. "
10/01/2002 - "These results support the hypothesis that alpha-hydroxytamoxifen is a major proximate tamoxifen metabolite causing the initiation of tumors in the liver of rats treated with tamoxifen."
08/01/2001 - "Since the contribution of these alpha-hydroxy metabolites of tamoxifen to the induction of endometrial tumors is presently unknown, we compared the extent of DNA adduct formation in liver and selected non-hepatic tissues of female Sprague-Dawley rats treated by gavage with tamoxifen, alpha-hydroxytamoxifen, N-desmethyltamoxifen, alpha-hydroxy-N-desmethyltamoxifen and N,N-didesmethyltamoxifen, or intraperitoneal injection with tamoxifen, alpha-hydroxytamoxifen, 3-hydroxytamoxifen and 4-hydroxytamoxifen. "
|2.||Endometrial Neoplasms (Endometrial Cancer)
|3.||Breast Neoplasms (Breast Cancer)
|4.||Body Weight (Weight, Body)
11/18/2007 - "To test this hypothesis directly, we compared the extent of tamoxifen-DNA adduct formation in rats co-administered 27micromol N,N-didesmethyltamoxifen per kg body weight and either 27micromol tamoxifen per kg body weight or 27micromol alpha-hydroxytamoxifen per kg body weight daily for 7days. "
|2.||DNA (Deoxyribonucleic Acid)